Related Experiment Video
Updated: Sep 22, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Targeting DUSP Activity as a Treatment for High-Grade Serous Ovarian Carcinoma
Brooke E Sanders1,2, Tomomi M Yamamoto3, Alexandra McMellen3
1Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, The University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Abstract:
Identifying novel, durable treatments for high-grade serous ovarian cancer (HGSOC) is paramount to extend both progression-free survival (PFS) and overall survival (OS) in patients afflicted with this disease. Dual-specificity phosphatase 1 (DUSP1) was identified as one of seven genes that may significantly affect prognosis in patients with HGSOC; however, the role of DUSP inhibition (DUSPi) in the treatment of HGSOC remains largely unknown. In this study, we show that DUSP1 is highly expressed in HGSOC and confers worse PFS and OS. Further, we corroborate data that show DUSP1 expression is directly associated with therapy resistance. Using a tissue microarray of 137 different serous ovarian carcinomas, we demonstrate the high expression of DUSP1 in primary and recurrent serous ovarian cancer. In both acquired and de novo therapy HGSOC-resistant models, DUSPi both inhibited cellular proliferation and promoted cell death. RPPA analysis of HGSOC cells revealed DUSPi led to the differential regulation of several pathways, including AMPK and mTORC. Further, in a patient-derived xenograft HGSOC model, DUSPi significantly inhibited tumor progression.
Insights
Dual-specificity phosphatase 1 (DUSP1) is highly expressed in high-grade serous ovarian cancer (HGSOC), worsening patient survival and therapy resistance. DUSP1 inhibition (DUSPi) shows promise by reducing proliferation and promoting cell death in HGSOC models.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- High-grade serous ovarian cancer (HGSOC) requires novel treatments to improve progression-free survival (PFS) and overall survival (OS).
- Dual-specificity phosphatase 1 (DUSP1) is implicated in HGSOC prognosis, but its therapeutic role is unexplored.
- DUSP1 expression is linked to poorer outcomes and therapy resistance in HGSOC.
Purpose of the Study:
- To investigate the role of DUSP1 in HGSOC and evaluate the therapeutic potential of DUSP1 inhibition (DUSPi).
Main Methods:
- Analysis of DUSP1 expression in 137 serous ovarian carcinomas using tissue microarrays.
- Assessment of DUSPi effects on proliferation and cell death in acquired and de novo HGSOC-resistant models.
- Reverse-phase protein array (RPPA) analysis to identify DUSPi-regulated pathways (e.g., AMPK, mTORC).
- Evaluation of DUSPi efficacy in a patient-derived xenograft HGSOC model.
Main Results:
- DUSP1 is highly expressed in primary and recurrent HGSOC, correlating with worse PFS and OS.
- DUSP1 expression is associated with resistance to standard therapies.
- DUSPi effectively inhibited proliferation and induced cell death in HGSOC-resistant models.
- DUSPi treatment modulated key signaling pathways, including AMPK and mTORC.
- DUSPi significantly suppressed tumor progression in a patient-derived xenograft model.
Conclusions:
- DUSP1 is a significant negative prognostic factor and a marker of therapy resistance in HGSOC.
- DUSP1 inhibition represents a promising therapeutic strategy for high-grade serous ovarian cancer, warranting further clinical investigation.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:34Inhibition of Cdk Activity